VERTEX PHARMACEUTICALS INC / MA — Proxy Solicitation & Information Statement 2024

Apr 4, 2024

DEFA14A 1 lvrtx2024_defa14a.htm VERTEX PHARMACEUTICALS INC - DEFA14A html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" VERTEX PHARMACEUTICALS INCORPORATED - DEFA 14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. )

Filed by the Registrant Filed by a Party other than the Registrant

Check the appropriate box:
●	Preliminary Proxy Statement
●	Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))
●	Definitive Proxy Statement
●	Definitive Additional Materials
●	Soliciting Material under §240.14a-12

VERTEX PHARMACEUTICALS INCORPORATED

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):
●	No fee required.
●	Fee paid previously with preliminary materials.
●	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.